Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR
Using SABR alone, the omission of upfront EXTREME-based chemotherapy and maintenance cetuximab in oligometastatic patients with HNSCC resulted in similar survival but much less severe QoL deterioration and fewer toxicity rates. SABR alone could be a reasonable alternative in oligometastatic patients with HNSCC.
Authors
- S. Chapet
- Christian Borel (ORCID: https://orcid.org/0000-0002-7710-2086)
- Audrey Rambeau (ORCID: https://orcid.org/0000-0003-0241-4453)
- Jean Faivre (ORCID: https://orcid.org/0000-0002-2617-3562)
- F. Huguet (ORCID: https://orcid.org/0000-0002-5302-5784)
- Y. Pointreau (ORCID: https://orcid.org/0000-0002-2442-2879)
- Jérôme Fayette (ORCID: https://orcid.org/0000-0002-8126-7019)
- M. Bosset
- S. Racadot
- Yungan Tao (ORCID: https://orcid.org/0000-0002-6916-5263)
- Adeline Péchery
- Juliette Thariat (ORCID: https://orcid.org/0000-0003-4755-496X)
- Jean Bourhis (ORCID: https://orcid.org/0000-0001-5162-1171)
- S. Guihard (ORCID: https://orcid.org/0000-0002-5630-8667)
- J. Castelli (ORCID: https://orcid.org/0000-0001-6128-1836)
- François‐Régis Ferrand
- Déwi Vernerey (ORCID: https://orcid.org/0000-0001-6399-926X)
- Xu-Shan Sun
- Antoine Falcoz
Institutions
- Institut Gustave Roussy (FR)
- Groupe d'Oncologie Radiothérapie Tête et Cou (FR)
- Centre François Baclesse (LU)
- Centre François Baclesse (FR)
Publication Details
- Journal
- International Journal of Radiation Oncology*Biology*Physics
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1016/j.ijrobp.2024.11.084
- Citations
- 18
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 10.44
Funders
- Seagen